Marker Therapeutics, Inc. 8-K Filing
Ticker: MRKR · Form: 8-K · Filed: Nov 14, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Nov 14, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Marker Therapeutics, Inc. (ticker: MRKR) to the SEC on Nov 14, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar).
How long is this filing?
Marker Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 547 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-11-14 07:20:47
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
Filing Documents
- tm2530894d1_8k.htm (8-K) — 25KB
- tm2530894d1_ex99-1.htm (EX-99.1) — 107KB
- tm2530894d1_ex99-1img001.jpg (GRAPHIC) — 15KB
- 0001104659-25-111940.txt ( ) — 329KB
- mrkr-20251114.xsd (EX-101.SCH) — 3KB
- mrkr-20251114_lab.xml (EX-101.LAB) — 33KB
- mrkr-20251114_pre.xml (EX-101.PRE) — 22KB
- tm2530894d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On November 14, 2025, Marker Therapeutics, Inc. (the " Company ") reported financial results for the third quarter ended September 30, 2025 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference. The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated November 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: November 14, 2025 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer